Blood: Blood red inhibits the body fluid B cell response in SCD patients to regulate the same immune risk

Red blood cell immunity remains an obstacle to safe and effective blood transfusions in sickle cell disease (SCD), but the associated risk factors remain unclear.
blood hemolysis, which is a hallmark of SCD, releases hemoglobin with effective immunomodulation activity.
, however, the role of in-blood hemolysis on SCD body fluid response (especially the same type of immunity) is not clear.
Mouli and others found that cell-free hemolybin inhibits human B-mother/pulp cell differentiation by inhibiting the DOCK8/STAT3 signaling path, and that the DOCK8/STAT3 signaling pathline is essential for B-cell biogasing and for raising hemoerin oxygenase 1 (HO-1) through its enzyme-promoting by-products carbon monoxide and bilirubin.
SCD B cells, which affect the activation of B cells, can be inhibited by exostopic hemoglobin, while B cells of the same type of immune system do not respond to hemoglobin inhibition and are easily differentiated into plasma cells.
was consistent with the difference in blood-soluble responses of B cells, the researchers found that DOCK8 B cell base levels increased in patients with SCD who were not Immune to the same type, and that HO-1-mediated active B-cell suppression was higher than in patients with the same type of Immune SCD.
in order to overcome the insensitivity of B cells of the same type of immune to hemoglobin and quinine treatment, the researchers screened several hemoglobin binding molecules and identified quinine as an effective inhibitor of B cell activity, thereby reversing the resistance of the same immunologist to hemoglobin inhibition.
inhibition of B cells only occurs in the presence of hemohemolytin and is induced by HO-1.
all, these data suggest that hemolytic blood can inhibit the response of B-cells, which may be a factor in the same immune risk in patients with SCD.
by restoring the sensitivity of B cells to hemoglobin, quinine may have the therapeutic potential to prevent and suppress the same kind of immunity in patients with SCD.
。